GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Trxade Health Inc (NAS:MEDS) » Definitions » Debt-to-EBITDA

Trxade Health (Trxade Health) Debt-to-EBITDA : -0.17 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Trxade Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Trxade Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $6.67 Mil. Trxade Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.43 Mil. Trxade Health's annualized EBITDA for the quarter that ended in Dec. 2023 was $-41.19 Mil. Trxade Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Trxade Health's Debt-to-EBITDA or its related term are showing as below:

MEDS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.33   Med: -0.62   Max: 12.61
Current: -0.6

During the past 13 years, the highest Debt-to-EBITDA Ratio of Trxade Health was 12.61. The lowest was -7.33. And the median was -0.62.

MEDS's Debt-to-EBITDA is ranked worse than
100% of 421 companies
in the Healthcare Providers & Services industry
Industry Median: 2.58 vs MEDS: -0.60

Trxade Health Debt-to-EBITDA Historical Data

The historical data trend for Trxade Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trxade Health Debt-to-EBITDA Chart

Trxade Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.33 -0.26 -0.24 -0.85 -0.62

Trxade Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.58 -1.23 -0.14 5.25 -0.17

Competitive Comparison of Trxade Health's Debt-to-EBITDA

For the Pharmaceutical Retailers subindustry, Trxade Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trxade Health's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Trxade Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Trxade Health's Debt-to-EBITDA falls into.



Trxade Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Trxade Health's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.67 + 0.434) / -11.472
=-0.62

Trxade Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.67 + 0.434) / -41.188
=-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Trxade Health  (NAS:MEDS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Trxade Health Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Trxade Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Trxade Health (Trxade Health) Business Description

Traded in Other Exchanges
N/A
Address
2420 Brunello Trace., Lutz, FL, USA, 33558
Trxade Health Inc is a health service IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey, and patient engagement in the U.S. Its product and services include Integra Pharma Solutions, LLC, Community Specialty Pharmacy, LLC, Delivmeds.com, Bonum Health Hub and Application, and others. its business is classified into reportable segments which are Trxade, Inc, Community Specialty Pharmacy, LLC, Integra Pharma, LLC, and Other, and the majority of the revenue comes from Trxade, Inc.
Executives
A. Jeffrey Newell director 645 CAMP DIXIE RD, PASCOAG RI 02859
Donald G. Fell director 17537 DARBY LANE, LUTZ FL 33558
Janet Huffman officer: CFO, PAO, PFO 5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Michael L Peterson director 17 CANARY COURT, DANVILLE CA 94526
Christine L. Jennings director 3840 LAND O' LAKES BLVD., LAND O' LAKES FL 34639
Prashant Patel director, 10 percent owner, officer: President 17537 DARBY LANE, LUTZ FL 33558
Pamela Tenaerts director PO BOX 15012, SARASOTA FL 34277
Gary Augusta director 700 NORTH BRAND BLVD., SUITE 1400, GLENDALE CA 91203
Howard A. Doss officer: CFO 17537 DARBY LANE, LUTZ FL 90067
Surendra K Ajjarapu director, 10 percent owner, officer: CEO 8604 BUTTON BUSH CT, TAMPA FL 33647
Donald V. Almeida director 1115 GUNN HIGHWAY, SUITE 202, ODESSA FL 33556
Charles L Pope director 4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Sandhya Ajjarapu 10 percent owner 17537 DARBY LANE, LUTZ FL 33558